Short‐term efficacy of tacrolimus in steroid‐refractory ulcerative colitis – experience in 130 patients von Schmidt, K. J., Herrlinger, K. R., Emmrich, J., Barthel, D., Koc, H., Lehnert, H., Stange, E. F., Fellermann, K., Büning, J.

Volltext

NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression von Wehkamp, J, Harder, J, Weichenthal, M, Schwab, M, Schäffeler, E, Schlee, M, Herrlinger, K R, Stallmach, A, Noack, F, Fritz, P, Schröder, J M, Bevins, C L, Fellermann, K, Stange, E F

Volltext

New treatment targets for inflammatory bowel disease? von Herrlinger, K R, Stange, E F

Volltext

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus von HERRLINGER, K. R., BARTHEL, D. N., SCHMIDT, K. J., BÜNING, J., BARTHEL, C. S., WEHKAMP, J., STANGE, E. F., FELLERMANN, K.

Volltext

ABCB1 Single‐Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis von Herrlinger, KR, Koc, H, Winter, S, Teml, A, Stange, EF, Fellermann, K, Fritz, P, Schwab, M, Schaeffeler, E

Volltext

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study von Herrlinger, K.R., Diculescu, M., Fellermann, K., Hartmann, H., Howaldt, S., Nikolov, R., Petrov, A., Reindl, W., Otte, J.M., Stoynov, S., Strauch, U., Sturm, A., Voiosu, R., Ammendola, A., Dietrich, B., Hentsch, B., Stange, E.F.

Volltext

Oral methotrexate in ulcerative colitis von Cummings, J. R. F., Herrlinger, K. R., Travis, S. P. L., Gorard, D. A., McIntyre, A. S., Jewell, D. P.

Volltext

Alterations in Pulmonary Function in Inflammatory Bowel Disease Are Frequent and Persist During Remission von Herrlinger, K R, Noftz, M K, Dalhoff, K, Ludwig, D, Stange, E F, Fellermann, K

Volltext

Mechanisms of Disease: defensins in gastrointestinal diseases von Wehkamp, Jan, Fellermann, Klaus, Herrlinger, Klaus R, Bevins, Charles L, Stange, Eduard F

Volltext

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues von Schmidt, K. J., Müller, N., Dignass, A., Baumgart, D. C., Lehnert, H., Stange, E. F., Herrlinger, K. R., Fellermann, K., Büning, J.

Volltext

Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease von KÜBLER, I., KOSLOWSKI, M. J., GERSEMANN, M., FELLERMANN, K., BEISNER, J., BECKER, S., ROTHFUSS, K., HERRLINGER, K. R., STANGE, E. F., WEHKAMP, J.

Volltext

Defensin pattern in chronic gastritis: HBD-2 is differentially expressed with respect to Helicobacter pylori status von Wehkamp, J, Schmidt, K, Herrlinger, K R, Baxmann, S, Behling, S, Wohlschläger, C, Feller, A C, Stange, E F, Fellermann, K

Volltext

Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis — A need for prophylaxis von Escher, M., Stange, E.F., Herrlinger, K.R.

Volltext

6‐Thioguanine — efficacy and safety in chronic active Crohn's disease von Herrlinger, K. R., Kreisel, W., Schwab, M., Schoelmerich, J., Fleig, W. E., Ruhl, A., Reinshagen, M., Deibert, P., Fellermann, K., Greinwald, R., Stange, E. F.

Volltext

The Religious Landscape of Revolutionary St. Petersburg, 1905-1918 von Herrlinger, K. Page

Volltext

Review article: interactions between genotype and response to therapy in inflammatory bowel diseases von HERRLINGER, K. R., JEWELL, D. P.

Volltext

Innate immunity and colonic inflammation: Enhanced expression of epithelial α-defensins von WEHKAMP, J, SCHWIND, B, HERRLINGER, K. R, BAXMANN, S, SCHMIDT, K, DUCHROW, M, WOHLSCHLÄGER, C, FELLER, A. C, STANGE, E. F, FELLERMANN, K

Volltext

Remission maintenance by tioguanine in chronic active Crohn's disease von Herrlinger, K. R., Deibert, P., Schwab, M., Kreisel, W., Fischer, C., Fellermann, K., Stange, E. F.

Volltext

6-Thioguanine Treatment in Inflammatory Bowel Disease: A Critical Appraisal by a European 6-TG Working Party von de Boer, N.K.H., Reinisch, W., Teml, A., van Bodegraven, A.A., Schwab, M., Lukas, M., Ochsenkühn, T., Petritsch, W., Knoflach, P., Almer, S., van der Merwe, S.W., Herrlinger, K.R., Seiderer, J., Vogelsang, H., Mulder, C.J.J.

Volltext

Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5‐ASA use von Herrlinger, K. R., Noftz, M. K., Fellermann, K., Schmidt, K., Steinhoff, J., Stange, E. F.

Volltext